 LONDON, June 24, 2022 GLOBE NEWSWIRE -- Freeline Therapeutics Holdings plc Nasdaq: FRLN today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therapy candidate FLT180a at the International Society on Thrombosis and Haemostasis ISTH Congress to be held in London, July 9-13, 2022. 